Company Overview
Snapshot
Founded in January 2007 by Prof. Havazelet Bianco-Peled, Sealantis operates with 11–50 employees. The company was acquired by Advanced Medical Solutions Group in January 2019, marking a significant exit in the Health Tech & Life Sciences sector.
Business overview
Sealantis develops protein-free tissue adhesives utilizing proprietary alga-mimetic formulations for a broad spectrum of surgical applications. Its core technology mimics the underwater adherence mechanism of algae. The company's product portfolio includes Seal-V, a surgical sealant for vascular procedures; Seal-G, a gastrointestinal bioresorbable sealant to prevent postsurgical leaks; and an Orthopedic Adhesion Barrier gel for joint injury recovery. Sealantis primarily serves the healthcare industry, operating within the Health Tech & Life Sciences sector, specifically focusing on Drug Delivery and Biomaterials & Tissue Engineering.
Strategic signal
In January 2018, Sealantis received CE Marking for its Seal-G surgical sealant for gastrointestinal procedures. This regulatory approval validated the product's safety and efficacy for the European market, signaling the company's readiness for broader commercialization and demonstrating a key milestone in its product development and market access strategy.
Company Intelligence Q&A
- What is Sealantis' primary focus?
- Sealantis specializes in developing protein-free tissue adhesives based on proprietary alga-mimetic formulations for various surgical applications, mimicking the underwater adherence mechanism of algae.
- When was Sealantis acquired and by whom?
- Sealantis was acquired by Advanced Medical Solutions Group in January 2019.
- What significant regulatory milestone did Sealantis achieve for its Seal-G product?
- In January 2018, Sealantis received CE Marking for its Seal-G surgical sealant, intended for gastrointestinal procedures.
- What is Seal-V?
- Seal-V is a surgical sealant developed by Sealantis designed for use in various vascular procedures to control bleeding.